Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

Conference call and webcast to be held today at 8:00 a.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., June 8, 2022 /PRNewswire/ -- Rigel Pharmaceutic...

Related Keywords

Canada ,Norway ,Serbia ,Georgia ,United States ,Australia ,Belarus ,Czech Republic ,Kalfa ,Stara Zagora ,Bulgaria ,Austria ,Russia ,Ukraine ,Germany ,Netherlands ,Massachusetts ,Belgium ,Italy ,France ,Spain ,Australian ,Canadian ,Raul Rodriguez ,Jodi Sievers ,Daiichi Sankyo ,David Kuter ,Eli Lilly ,Hematology Am Soc Hematol Educ Program ,Rigel Pharmaceuticals Inc ,Linkedin ,Twitter ,Drug Administration ,Professor Of Medicine At Harvard Medical School ,Nasdaq ,Exchange Commission ,Prnewswire Rigel Pharmaceuticals Inc ,Treatment Group ,Rigel Pharmaceuticals ,Pharmaceuticals Inc ,Western European ,Eastern European ,Western Europe ,Eastern Europe ,Functional Assessment ,Chronic Illness Therapy ,Adverse Event ,Chief Executive Officer ,Clinical Hematology ,Massachusetts General Hospital ,Harvard Medical School ,Webcast Today ,Investor Relations ,Orphan Drug ,Fast Track ,United Kingdom ,Tissue Trial ,Hematology Am Soc Hematol Educ ,Quarterly Report ,